Spyre Therapeutics Inc (NASDAQ:SYRE) shares, rose in value on Friday, July 11, with the stock price down by -1.69% to the previous day’s close as strong demand from buyers drove the stock to $15.69.
Actively observing the price movement in the last trading, the stock closed the session at $15.96, falling within a range of $15.475 and $15.96. The value of beta (5-year monthly) was 2.73. Referring to stock’s 52-week performance, its high was $40.26, and the low was $10.91. On the whole, SYRE has fluctuated by -15.46% over the past month.
With the market capitalization of Spyre Therapeutics Inc currently standing at about $946.94 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SYRE’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of SYRE currently trading nearly -0.49% and 1.53% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 49.56, while the 7-day volatility ratio is showing 5.11% which for the 30-day chart, stands at 7.83%. Furthermore, Spyre Therapeutics Inc (SYRE)’s beta value is 2.82.
A comparison of Spyre Therapeutics Inc (SYRE) with its peers suggests the former has fared considerably weaker in the market. SYRE showed an intraday change of -1.69% in last session, and over the past year, it shrunk by -32.60%%.
Data on historical trading for Spyre Therapeutics Inc (NASDAQ:SYRE) indicates that the trading volumes over the past 10 days have averaged 0.73 and over the past 3 months, they’ve averaged 577.11K. According to company’s latest data on outstanding shares, there are 60.28 million shares outstanding.
Nearly 14.97% of Spyre Therapeutics Inc’s shares belong to company insiders and institutional investors own 99.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 12.59 million shares as on 2025-06-13, resulting in a short ratio of 26.96. According to the data, the short interest in Spyre Therapeutics Inc (SYRE) stood at 2679.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 12.3 million. The stock has fallen by -41.97% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SYRE stock heading into the next quarter.
